AUROPHARMA - Swing Trade Analysis with AI Signals
Back to ListSwing Trade Rating: 3.9
| Stock Code | AUROPHARMA | Market Cap | 70,216 Cr. | Current Price | 1,209 ₹ | High / Low | 1,279 ₹ |
| Stock P/E | 34.7 | Book Value | 369 ₹ | Dividend Yield | 0.33 % | ROCE | 10.8 % |
| ROE | 8.65 % | Face Value | 1.00 ₹ | DMA 50 | 1,178 ₹ | DMA 200 | 1,163 ₹ |
| Chg in FII Hold | -0.26 % | Chg in DII Hold | 0.06 % | PAT Qtr | 581 Cr. | PAT Prev Qtr | 559 Cr. |
| RSI | 56.9 | MACD | 0.83 | Volume | 14,10,968 | Avg Vol 1Wk | 25,96,589 |
| Low price | 994 ₹ | High price | 1,279 ₹ | PEG Ratio | 8.14 | Debt to equity | 0.21 |
| 52w Index | 75.5 % | Qtr Profit Var | 8.16 % | EPS | 34.8 ₹ | Industry PE | 29.1 |
📊 AUROPHARMA (₹1,209) and ATUL (₹6,327) both show potential for swing trading but with different risk-reward profiles. AUROPHARMA trades above its 50 DMA (₹1,178) and 200 DMA (₹1,163), supported by neutral RSI (56.9) and slightly positive MACD (0.83). Fundamentals are moderate with P/E 34.7 vs industry 29.1, ROCE 10.8%, and ROE 8.65%. ATUL trades above both DMAs with strong MACD (46.1) and RSI (60.4), showing bullish momentum. Fundamentals are stable with EPS ₹176, debt-free balance sheet, and dividend yield 0.40%, though recent profit decline is a concern.
💡 Optimal Entry Price:
- AUROPHARMA: ₹1,170–₹1,190 (near DMA support).
- ATUL: ₹6,150–₹6,250 (near DMA support).
💡 Exit Strategy:
- AUROPHARMA: Exit near ₹1,260–₹1,280 if momentum sustains.
- ATUL: Exit near ₹6,700–₹6,800 unless trend strengthens further.
✅ Positive
- AUROPHARMA: Consistent profit growth (PAT ₹581 Cr. vs ₹559 Cr.), EPS ₹34.8, moderate debt-to-equity (0.21).
- ATUL: Debt-free, strong EPS ₹176, dividend yield 0.40%, bullish technical indicators.
⚠️ Limitation
- AUROPHARMA: High PEG ratio (8.14), FII holding reduced (-0.26%), moderate ROCE and ROE.
- ATUL: Decline in quarterly PAT (₹121 Cr. vs ₹172 Cr.), low trading volume compared to average, FII holding reduced (-0.86%).
📉 Company Negative News
- AUROPHARMA: Valuation slightly above industry average, limited dividend yield.
- ATUL: Profit decline in recent quarter raises concerns.
📈 Company Positive News
- AUROPHARMA: Stable earnings growth, strong presence in pharma sector, resilient demand.
- ATUL: Debt-free balance sheet, strong book value (₹1,973), consistent dividend payout.
🏭 Industry
- AUROPHARMA: Industry PE ~29.1, company trades at slight premium due to growth expectations.
- ATUL: Industry PE ~27.4, company trades at premium supported by strong fundamentals.
🔎 Conclusion
ATUL is technically stronger with bullish momentum and debt-free fundamentals, making it a better swing trade candidate despite recent profit decline. AUROPHARMA offers moderate upside with stable earnings but trades at a premium. Traders can enter AUROPHARMA near ₹1,170–₹1,190 and exit around ₹1,260–₹1,280. ATUL offers entry near ₹6,150–₹6,250 with exit around ₹6,700–₹6,800. Both require disciplined stop-loss management due to valuation